A B S T R AC T
Objective: The aim of this study was to evaluate the role of secondary cytoreductive surgery in Asian patients with recurrent ovarian cancer and to assess prognostic variables on overall post-recurrence survival time. Methods: We conducted a retrospective review of patients with recurrent ovarian cancer who underwent secondary cytoreduction at the Gynaecological Cancer Center at the KK Women's and Children's Hospital, Singapore, between 1999 and 2009. Eligible patients included those who had been firstly treated by primary cytoreductive surgery and followed by adjuvant chemotherapy and had a period of clinical remission of at least six months and subsequently underwent secondary cytoreductive surgery for recurrence. Univariate analysis was performed to evaluate various variables influencing the overall survival. Results: Twenty-five patients met our eligibility criteria. The median age was 52 years (range=31-78 years). The median time from completion of primary treatment to recurrence was 25.1 months (range=6. 4-83.4) . Secondary cytoreduction was optimal in 20 of 25 patients (80%). The median follow-up duration was 38.9 months (range=17.8-72.4) and median overall survival time was 33.1 months (95% confidence interval, 15.3-undefined.). Ten (40.0%) patients required bowel resection, but no end colostomy was performed. One (4.0%) patient had wedge resection of the liver, one (4.0%) had a distal pancreatectomy, one (4.0%) had a unilateral nephrectomy, and one (4.0%) had adrenalectomy. There were no operative deaths. The overall survival of patients who responded to secondary cytoreductive surgery and adjuvant chemotherapy was significantly longer than those patients who did not respond to the treatment. Of those patients who responded to the surgical management, patients with clear cell carcinoma fared well compared to those with the endometrioid, mucinous adenocarcinoma, and papillary serous type (p<0.001). Complete secondary cytoreductive surgery appeared to have some relationship to overall survival but was not statistically significant. Conclusion: In carefully selected patients with recurrent ovarian cancer, optimal cytoreductive surgery is possible and in a subgroup of patients who respond to surgery and chemotherapy survival is significantly longer. treatment-free survival (first recurrence from six months to 24 months) and postoperative residual disease, described as "<0.5mm, " "microscopic, " or "none." [3] [4] [5] [6] A meta-analysis by Bristow et al, 7 supports the role of secondary cytoreductive surgery and proved that residual disease after debulking surgery is an important determinant of survival. New surgical options are emerging for selected patients with recurrent ovarian cancer, such as complete cytoreductive surgery including peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). These surgeries aim at achieving minimal or no residual disease and targeting the remaining residual disease with heated intraperitoneal chemotherapy. Again, this is based on the principle of using aggressive primary cytoreductive surgery with intraperitoneal chemotherapy for advanced ovarian cancer. Chi et al, 8 demonstrated that along with traditional primary cytoreductive surgery, incorporating procedures such as resection of diaphragm peritonectomy, splenectomy, distal pancreatectomy, partial hepatectomy, cholecystectomy, and portal caval dissection in order to address tumor deposits in the upper abdomen has led to improved five-year progression-free survival.
The question of whether a change in the surgical paradigm should occur for recurrent ovarian cancer remains a topic of debate. The primary objective of this study was to evaluate our experience with secondary cytoreductive surgery for Asian patients with recurrent ovarian cancer and to evaluate various prognostic variables on overall post-recurrence survival time.
M ET H O D S
After obtaining Institutional Review Board approval, the Gynaecological Cancer Center at KK Women's and Children's Hospital, Singapore, database was reviewed to identify patients with recurrent ovarian cancer who underwent secondary cytoreductive surgery from 1999 to 2009. Only those patients with epithelial ovarian cancer who had primary surgery followed by platinum-based adjuvant chemotherapy and who were in clinical remission for six months were included in the study. All patients with recurrent ovarian cancer were presented at multidisciplinary tumor board meeting and, based on their clinical and radiological findings, patients who were deemed to have the resectable disease were selected for secondary cytoreductive surgery. The criteria for optimal cytoreductive surgery varied during the study period, before 2002 it was taken as <2cm and after that it was <1cm. Following surgery, patients were treated with a platinum-based chemotherapy combination and were changed to second-or thirdline regimens based on their response. Twenty-five patients were identified from the database that fulfilled our criteria. Data were retrieved for age, details of primary surgery, stage, histological type, grade, adjuvant chemotherapy treatment, secondary debulking surgery if optimal or sub-optimal, followup, and survival outcome.
Disease-free interval (DFI) was calculated as the time (in months) from the date of completion of chemotherapy following primary cytoreductive surgery to the date of recurrence. Overall survival (OS) was calculated as the time (in months) from the date of completion of chemotherapy following secondary cytoreductive surgery to the date of death from all causes or censored at the date of last followup. Disease-free survival (DFS) was calculated as the time (in months) from the date of completion of chemotherapy following secondary cytoreductive surgery to the date of recurrence or death from all causes, or censored at date of last follow-up. Patients who had progressive disease following secondary cytoreductive surgery were excluded from the analysis of DFS. Median follow-up duration was estimated using the reverse Kaplan-Meier method. The Kaplan-Meier method was used to determine the survival functions for DFI, OS, and DFS. Median DFI, OS, and DFS were derived, and 95% confidence intervals (CI) were calculated using the log-log method. One-, two-and three-year survival rates were also derived from the Kaplan-Meier survivor function. The log-rank test was used to determine if there was a difference in survival curves between different groups of patients. A two-sided p-value of less than 0.050 was taken as significant. All analyzes were performed using Stata 9.0 software (StataCorp, Texas, US).
R E SU LTS
During the study period, 25 patients were identified who underwent secondary cytoreductive surgery for recurrent ovarian cancer. Demographics and clinical characteristics of the patients at the time of diagnosis of recurrence are summarized in Table 1 . The median age at the time of recurrence was 52 years (range=31-78); 13 (52.0%) patients initially had stage III disease. At primary cytoreductive surgery, 20 patients (80.0%) had optimal, and five (20.0%) had suboptimal cytoreductive surgery. After primary surgery, all patients received platinum-based chemotherapy. The median DFI was 25.1 months (range=6.4-83.4). At the 5% significance level, only tumor grade was significantly (p<0.009) related to the disease-free interval [ Table 2 ]. The median disease-free interval was 63.2, 16.7, and 22.4 months in disease grades one, two, and three, respectively. Patients with grade two and three tumors had shorter DFI compared to patients with grade one disease.
Patients with optimal versus suboptimal primary cytoreductive surgery also appeared to have some relationship with the DFI [Table 3 ]; however, this was not statistically significant (p<0.348). This could be because the criteria for optimal cytoreduction varied in the study group.
Optimal secondary cytoreduction was achieved in 20 (80.0%) patients, five (20.0%) had suboptimal debulking. Of those five patients, three had nodal metastasis adherent to a major vessel, and the other two patients had a frozen pelvis with the disease extending up to the pelvic sidewall. Ten (40.0%) patients required bowel resection, but no end colostomy was performed. One (4.0%) patient had wedge resection of the liver, one (4.0%) had distal pancreatectomy, one (4.0%) had a unilateral nephrectomy, and one (4.0%) had adrenalectomy. There was no operative mortality. Following secondary cytoreductive surgery, 23 (85.2%) patients had adjuvant platinum-based chemotherapy and two patients refused chemotherapy. Patients who did not respond to platinum-based chemotherapy were treated with second-and third-line chemotherapeutic agents.
The median follow-up duration for all patients was 38.9 months (95% CI, 17.8-72.4 months). Median overall survival was not reached for many groups, and 95% confidence intervals were not fully defined due to a small number of events (11 deaths out of 25 patients in total). Of the 25 patients, 12 (48.0%) developed a second recurrence and of these five patients underwent a third cytoreductive surgery, and seven patients received palliative chemotherapy. At the 5% significant level, only cancer stage was significantly related to overall survival. Stage two and three patients were shown to do have a worse overall survival than stage one cancer patients [ Table 3 ]. From the Kaplan-Meier plots, secondary cytoreduction being optimal or suboptimal also appeared to have some relationship with overall survival, but was not statistically significant. Additionally, patients responding to secondary treatment (i.e. secondary cytoreductive surgery plus chemotherapy) were analyzed, and those patients who had progressive disease after completion of secondary treatment were termed non-responders. Non-responders had a significantly shorter OS compared to responders (p=0.002) [ Figure 1 ].
The DFS of those 18 patients who responded to secondary cytoreductive surgery was analyzed. Only histopathology was significantly related to diseasefree survival at the 5% significance level [ Table 4 ]. Of the histopathology types, patients with clear-cell carcinoma showed better survival (p=0.002). Overall, after a median follow-up time of 38.9 months, eight patients (32.0%) were alive with no evidence of disease, six (24.0%) were alive with disease, and eleven (44.0%) had died. Figure 1 shows the overall survival following secondary cytoreductive surgery. The overall one-, two-and three-year survival rate following secondary cytoreductive surgery was 78.1%, 56.1%, and 44.9%, respectively. Univariate analysis was performed on various clinical variables such as DFI (fewer than vs. more than 12 months), disease stage, tumor grade, and optimal versus suboptimal surgery. There was no significant difference in any of these variables, but those patients who responded to secondary cytoreductive surgery had a longer survival period than not responders.
D I S C U S S I O N
The role of primary cytoreductive surgery is well established in the management of epithelial ovarian cancer. Numerous investigators have documented improved survival after secondary cytoreductive surgery, but still lack evidence-based protocols for managing such patients. This is partly because most of the literature on this subject are non-randomized, retrospective studies. As these recurrent tumors develop resistance to platinum-based chemotherapy, and due to their heterogeneous behavior, the role of aggressive secondary cytoreductive surgery has always been questioned. Factors that affect survival following secondary cytoreductive surgery are disease-free interval following primary cytoreductive surgery and volume of residual disease following secondary cytoreductive surgery. Several studies, including ours, showed that the volume of residual disease after secondary cytoreduction had some effect on OS. We looked into the studies published on this subject over the last three decades. Since these studies were published between 1983 to 2012, the criteria for optimal cytoreduction varied from <2.5cm to no gross disease, we tabulated them according to the criteria used to see the rate of optimal secondary cytoreduction and their OS [ Table 5 ]. During the period where the optimal cytoreduction was defined as <2.5 to >1.0cm, optimal cytoreduction was achieved in 37.5%-90.5% of cases and overall survival in these patients ranged from 10.0-45.8 months. When it was defined as less than <1.0cm optimal cytoreduction was achieved in 33.0%-100% of cases and the OS ranged from 11-48 months. With current definition of optimal cytoreduction being <0.25cm to no gross disease, optimal cytoreduction was achieved in 22.2%-100.0% of cases and OS in these patients was 22.5-60 months.
Various authors have shown that one important factor to have a significant influence on OS following secondary cytoreduction was the DFI (recurrencefree interval): a longer DFI was associated with more prolonged survival. 3, 17, 18, 22, 66 However, some studies have shown that DFI was not a significant variable. 4, 8, 9, 44, 49 In our study, the univariate analysis did not reveal any factors that affected the duration of OS. Our analysis was inherently limited by the potential for selection bias as, being a retrospective study, it covered a time during which concepts of optimal cytoreductive surgery and available adjuvant therapies evolved. This could have influenced the prognostic impact of individual variables on survival.
C O N C LU S I O N Our experience confirms that in a selected group of patients secondary cytoreduction improves survival of patients with ovarian cancer whose disease recurs at least six months after the primary treatment. Whether this is due to the surgical procedure itself or tumor biology remains unclear. There is urgent need for a large multi-institutional prospective randomized trial to analyze various variables and selection criteria for secondary cytoreductive surgery.
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